Thomas J Carmody

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9926294/publications.pdf

Version: 2024-02-01

54 5,201 22
papers citations h-inc

22 53
h-index g-index

55 55 all docs citations

55 times ranked 6620 citing authors

#	Article	IF	CITATIONS
1	The 16-Item quick inventory of depressive symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biological Psychiatry, 2003, 54, 573-583.	0.7	2,981
2	The Inventory of Depressive Symptomatology (IDS): Clinician (IDS-C) and Self-Report (IDS-SR) ratings of depressive symptoms. International Journal of Methods in Psychiatric Research, 2000, 9, 45-59.	1.1	328
3	Establishing moderators and biosignatures of antidepressant response in clinical care (EMBARC): Rationale and design. Journal of Psychiatric Research, 2016, 78, 11-23.	1.5	216
4	The Montgomery \tilde{A} , sberg and the Hamilton ratings of depression: A comparison of measures. European Neuropsychopharmacology, 2006, 16, 601-611.	0.3	183
5	Exercise as an Augmentation Treatment for Nonremitted Major Depressive Disorder. Journal of Clinical Psychiatry, 2011, 72, 677-684.	1.1	177
6	Test–retest reliability of freesurfer measurements within and between sites: Effects of visual approval process. Human Brain Mapping, 2015, 36, 3472-3485.	1.9	136
7	Pretreatment Rostral Anterior Cingulate Cortex Theta Activity in Relation to Symptom Improvement in Depression. JAMA Psychiatry, 2018, 75, 547.	6.0	125
8	Effect of Sertraline on Depressive Symptoms in Patients With Chronic Kidney Disease Without Dialysis Dependence. JAMA - Journal of the American Medical Association, 2017, 318, 1876.	3.8	99
9	Moderation of the Relationship Between Reward Expectancy and Prediction Error-Related Ventral Striatal Reactivity by Anhedonia in Unmedicated Major Depressive Disorder: Findings From the EMBARC Study. American Journal of Psychiatry, 2015, 172, 881-891.	4.0	87
10	Effect of Intrinsic Patterns of Functional Brain Connectivity in Moderating Antidepressant Treatment Response in Major Depression. American Journal of Psychiatry, 2020, 177, 143-154.	4.0	76
11	Randomized Controlled Trial Comparing Exercise to Health Education for Stimulant Use Disorder. Journal of Clinical Psychiatry, 2017, 78, 1075-1082.	1.1	53
12	Pretreatment Rostral Anterior Cingulate Cortex Connectivity With Salience Network Predicts Depression Recovery: Findings From the EMBARC Randomized Clinical Trial. Biological Psychiatry, 2019, 85, 872-880.	0.7	48
13	Response in Relation to Baseline Anxiety Levels in Major Depressive Disorder Treated with Bupropion Sustained Release or Sertraline. Neuropsychopharmacology, 2001, 25, 131-138.	2.8	45
14	A COMPREHENSIVE EXAMINATION OF WHITE MATTER TRACTS AND CONNECTOMETRY IN MAJOR DEPRESSIVE DISORDER. Depression and Anxiety, 2016, 33, 56-65.	2.0	43
15	Early Improvement in Work Productivity Predicts Future Clinical Course in Depressed Outpatients: Findings From the CO-MED Trial. American Journal of Psychiatry, 2016, 173, 1196-1204.	4.0	40
16	Making clinicians lives easier: Guidance on use of the QIDS self-report in place of the MADRS. Journal of Affective Disorders, 2006, 95, 115-118.	2.0	33
17	Sex differences in the association of baseline c-reactive protein (CRP) and acute-phase treatment outcomes in major depressive disorder: Findings from the EMBARC study. Journal of Psychiatric Research, 2019, 113, 165-171.	1.5	33
18	Fatigue in Nondialysis Chronic Kidney Disease: Correlates and Association with Kidney Outcomes. American Journal of Nephrology, 2019, 50, 37-47.	1.4	31

#	Article	IF	CITATIONS
19	A Randomized, Double-Blind, Placebo-Controlled Trial of Citicoline for Cocaine Dependence in Bipolar I Disorder. American Journal of Psychiatry, 2015, 172, 1014-1021.	4.0	30
20	Test-retest reliability of cerebral blood flow in healthy individuals using arterial spin labeling: Findings from the EMBARC study. Magnetic Resonance Imaging, 2018, 45, 26-33.	1.0	28
21	Discovery and replication of cerebral bloodÂflow differences in major depressive disorder. Molecular Psychiatry, 2020, 25, 1500-1510.	4.1	28
22	Early Improvement in Psychosocial Function Predicts Longer-Term Symptomatic Remission in Depressed Patients. PLoS ONE, 2016, 11, e0167901.	1.1	26
23	Decision-making processes as predictors of relapse and subsequent use in stimulant-dependent patients. American Journal of Drug and Alcohol Abuse, 2016, 42, 88-97.	1.1	23
24	Pretreatment Reward Sensitivity and Frontostriatal Resting-State Functional Connectivity Are Associated With Response to Bupropion After Sertraline Nonresponse. Biological Psychiatry, 2020, 88, 657-667.	0.7	23
25	Statistical analysis plan for stage 1 EMBARC (Establishing Moderators and Biosignatures of) Tj ETQq1 1 0.784314 6, 22-30.	rgBT /Ove	erlock 10 Tf 22
26	Positive and negative valence systems in major depression have distinct clinical features, response to antidepressants, and relationships with immunomarkers. Depression and Anxiety, 2020, 37, 771-783.	2.0	22
27	Comprehensive phenotyping of depression disease trajectory and risk: Rationale and design of Texas Resilience Against Depression study (T-RAD). Journal of Psychiatric Research, 2020, 122, 22-32.	1.5	21
28	A Systematic Review and Meta-Analysis of Depression and Protein–Energy Wasting in Kidney Disease. Kidney International Reports, 2020, 5, 318-330.	0.4	20
29	Cerebral Blood Perfusion Predicts Response to Sertraline versus Placebo for Major Depressive Disorder in the EMBARC Trial. EClinicalMedicine, 2019, 10, 32-41.	3.2	19
30	Brain imaging demonstrates a reduced neural impact of eating in obesity. Obesity, 2016, 24, 829-836.	1.5	17
31	Anxiety and anhedonia in depression: Associations with neuroticism and cognitive control. Journal of Affective Disorders, 2019, 245, 1070-1078.	2.0	17
32	Affect Following First Exercise Session as a Predictor of Treatment Response in Depression. Journal of Clinical Psychiatry, 2016, 77, 1036-1042.	1.1	15
33	Atypical depressive symptoms as a predictor of treatment response to exercise in Major Depressive Disorder. Journal of Affective Disorders, 2016, 200, 156-158.	2.0	15
34	A psychometric evaluation of the Concise Health Risk Tracking Self-Report (CHRT-SR)- a measure of suicidality-in patients with stimulant use disorder. Journal of Psychiatric Research, 2018, 102, 65-71.	1.5	14
35	The Concise Health Risk Tracking-Self Report: Psychometrics within a placebo-controlled antidepressant trial among depressed outpatients. Journal of Psychopharmacology, 2019, 33, 185-193.	2.0	14
36	Predicting future suicidal events in adolescents using the Concise Health Risk Tracking Self-Report (CHRT-SR). Journal of Psychiatric Research, 2020, 126, 19-25.	1.5	14

#	Article	IF	Citations
37	Association of Novel ALX4 Gene Polymorphisms with Antidepressant Treatment Response: Findings from the CO-MED Trial. Molecular Neuropsychiatry, 2018, 4, 7-19.	3.0	12
38	Performance of depression rating scales in patients with chronic kidney disease: an item response theory-based analysis. General Hospital Psychiatry, 2016, 42, 60-66.	1.2	9
39	A complier average causal effect analysis of the Stimulant Reduction Intervention using dosed exercise study. Contemporary Clinical Trials Communications, 2018, 10, 1-8.	0.5	9
40	The Promoting Activity in Cancer Survivors (PACES) trial: a multiphase optimization of strategy approach to increasing physical activity in breast cancer survivors. BMC Cancer, 2018, 18, 744.	1,1	7
41	The Concise Health Risk Tracking Selfâ€Report (CHRTâ€SR) assessment of suicidality in depressed outpatients: A psychometric evaluation. Depression and Anxiety, 2019, 36, 313-320.	2.0	7
42	Multi-Omics Characterization of Early- and Adult-Onset Major Depressive Disorder. Journal of Personalized Medicine, 2022, 12, 412.	1.1	7
43	Inflammation and Response to Sertraline Treatment in Patients With CKD and Major Depression. American Journal of Kidney Diseases, 2020, 75, 457-460.	2.1	6
44	Exploration of baseline and early changes in neurocognitive characteristics as predictors of treatment response to bupropion, sertraline, and placebo in the EMBARC clinical trial. Psychological Medicine, 2022, 52, 2441-2449.	2.7	6
45	The effectiveness of enhanced evidence-based care for depressive disorders: a meta-analysis of randomized controlled trials. Translational Psychiatry, 2021, 11, 531.	2.4	6
46	Adiponectin moderates antidepressant treatment outcome in the combining medications to enhance depression outcomes randomized clinical trial. Personalized Medicine in Psychiatry, 2018, 9-10, 1-7.	0.1	5
47	Psychometrics of the Self-Report Concise Associated Symptoms Tracking Scale (CAST-SR). Journal of Clinical Psychiatry, 2018, 79, 41-47.	1.1	5
48	Baseline medical comorbidities in adults randomized in the STRIDE trial for psychostimulant use disorders. American Journal on Addictions, 2016, 25, 215-220.	1.3	4
49	Depression and the Effect of Sertraline on Inflammatory Biomarkers in Patients with Nondialysis CKD. Kidney360, 2020, 1, 436-446.	0.9	4
50	Neural substrates of emotional conflict with anxiety in major depressive disorder: Findings from the Establishing Moderators and biosignatures of Antidepressant Response in Clinical Care (EMBARC) randomized controlled trial. Journal of Psychiatric Research, 2022, 149, 243-251.	1.5	4
51	Comparison of inflammatory markers as moderators of depression outcomes: A CO-MED study. Journal of Affective Disorders, 2021, 295, 1066-1071.	2.0	3
52	Psychometric and Clinical Evaluation of the Clinician (VQIDS-C5) and Self-Report (VQIDS-SR5) Versions of the Very Quick Inventory of Depressive Symptoms. Neuropsychiatric Disease and Treatment, 2022, Volume 18, 289-302.	1.0	3
53	Long-term results of interstitial implant in locally advanced cervical cancer: A retrospective study of 50 cases. Radiation Oncology Investigations, 1996, 4, 33-40.	1.3	2
54	Moderators of treatment response to exercise in participants with stimulant use disorder: Exploratory results from the Stimulant Reduction using Dosed Exercise (STRIDE)CTN-0037 study. Mental Health and Physical Activity, 2021, 21, 100421.	0.9	0